This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Vivian Xie
21 Dec 2022

Strategic partnership between AstraZeneca and G42 Healthcare to increase pharmaceutical manufacturing in Abu Dhabi

A comprehensive, long-term partnership agreement between AstraZeneca and G42 Healthcare is set to enhance local drug manufacturing in Abu Dhabi, UAE, and bolster pharmaceutical manufacturing innovation within the country.

Pharmaceutical giant AstraZeneca has announced their strategic partnership agreement with G42 Healthcare, a healthcare company powered by AI technology, to locally manufacture innovative drugs in Abu Dhabi. The collaboration builds upon ongoing efforts by the Department of Health – Abu Dhabi (DoH), the National Strategy for Industry and Advanced Technology, and the Make it in the Emirates initiative to bolster Abu Dhabi’s healthcare environment.

Efforts to enhance the UAE’s position as an attractive destination for both local and global investors in the pharmaceutical industry has focused on supporting growth within the country, and adopting advanced technologies to centre the country as a global hub for pharmaceutical manufacturing and future industries. The agreement between AstraZeneca and G42 Healthcare will further focus on four main areas: localising innovative industries, R&D, and both innovation and sustainability at the global scale. The multi-year process was outlined by a delegation of representatives from government bodies, G42 Healthcare, and AstraZeneca at the signing of the binding agreement on December 20, 2022.  

The size of Abu Dhabi’s manufacturing sector is set to double by 2031, expanding the city’s life sciences’ research and development impression and incentivise innovation across all streams of healthcare, including drug development and manufacturing. Collaboration will be essential to the bolstering of exports and delivery of breakthrough science in support of getting essential medications to patients in the UAE. Sustainable solutions to healthcare issues within the nation will adhere to international best practice standards and will aim to balance both economic growth and sustainability for its people and the environment. The agreement will also align with the objectives set out by the Make it in the Emirates campaign, which provides a supportive legislative framework, financing solutions, and infrastructure to create investment opportunities within the UAE drug manufacturing space. The DoH also hopes to play a critical role in the creation of new job opportunities within the UAE and attract highly skilled workers to the nation. HE Dr. Jamal Mohammed Al Kaabi, Undersecretary at the DoH, commented: “Under the directives of the UAE’s wise leadership, our country continues to be a strong proponent of research and innovation as part of our ongoing efforts to bolster the healthcare industry. Abu Dhabi continues to lead on critical research with the support of international partners to explore the sustainability and resilience of the global healthcare sector while ensuring the delivery of quality healthcare for patients.” 

Cluster President for GCC and Pakistan at AstraZeneca Sameh ElFangary added: “AstraZeneca is honoured to be a long-term trusted partner of the UAE in bringing innovative healthcare locally, and we applaud Abu Dhabi’s ambition to become a regional life sciences hub. We are now taking our comprehensive existing partnership with G42 Healthcare to new heights, accelerating it across local manufacturing, research, innovation, and sustainability. I’m confident that this partnership will contribute greatly to advancing a sustainable health ecosystem that enables transforming the patient outcomes.” 

Source: AstraZenca, G42 Healthcare enter strategic partnership to manufacture pharmaceutical products in Abu Dhabi ( 

Vivian Xie
Editor - Custom Content

Related News